ClinicalTrials.gg
CompletedNCT00659997ALBvLEVUpdated Apr 17, 2008

Efficacy Albendazole and Levamisole Against STH on Unguja

A Phase 4 interventional study of Albendazole and Levamisole in Ascariasis and Trichuriasis, sponsored by Natural History Museum, United Kingdom. Completed at 1 site in Tanzania. Open to female participants aged 1 Year to 45 Years. Per ClinicalTrials.gov, last updated 2008-04-17.

Sponsored by Natural History Museum, United Kingdom · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
1 Year to 45 Years
Sex
Female
01

Study summary

Field epidemiological studies undertaken during 2005 in four village locations in Northern Unguja, Zanzibar examined mothers and their pre-school aged children for helminth infections.

The prevalence of Ascaris lumbricoides was found to have remained relatively high despite community-wide treatment with the mass administration of Albendazole (a WHO recommended de-wormer) in coordination with community vitamin A supplementation.

One hypothesis for this is that the children and mothers had Ascaris infections more tolerant to Albendazole that subsequently failed to clear. It is necessary to compare the present drug efficiency of Albendazole (first-line de-wormer) with Levamisole (second-line de-wormer) on STH infections such patients a case-control setting to shed light on the putative resistance of local Ascaris/Trichuris to albendazole.

In so doing, this should clarify whether there is resistance developing towards Albendazole and have possible implications for introducing combination therapies of Levamisole and Albendazole for first line de-worming mothers and their children in the future.

Read the detailed description

The study was conducted in 10 villages on Unguja Island representative of urban, semi-urban and rural environments. After liaison with the local Shehia (the elected community leader) mothers and their children aged between 6 months and 5 years old were invited to attend a walk-in mobile clinic. In accordance with WHO sample size recommendations of 30 individuals per site and to cater for drop-out/non-compliance, target enrolment was about 50 mother and child pairs at each study village.

Stool specimens were transported to the Helmtin Control Laboratory Unguja laboratory for visual inspection of stool consistency and presence of blood, after which a single Kato-Katz thick smear (41.7mg) was prepared. Eggs of all STH species were counted by inspection at 100x microscopy and expressed as a tally of eggs per gram (EPG). To ensure consistency of egg counts, slides were read by the same two technicians for each study village.

10 Mother and child pairs found positive for Ascaris and/or Trichuris were randomised, by coin tossing, to receive either a single tablet of ALB (400mg) or an appropriate dose of LEV (2.5 mg/kg). A parasitological follow-up took place 18 days after treatment where a requested stool sample was analyzed by a single Kato-Katz thick smear for assessment of STH clearance. In accordance with WHO's 'no survey without service' all attendees were given an additional ALB tablet.

02

Conditions studied

  • Ascariasis
  • Trichuriasis

Browse trials for

Keywords

  • Ascariasis
  • Trichuriasis
  • Drug resistance
03

In context

Trichuriasis

30 studies on the registry are indexed under Trichuriasis; 7 are open to participants now.

This study's enrollment of 20 is below the median of 315 across 27 interventional studies indexed under Trichuriasis.

Browse Trichuriasis studies →

Lead sponsor

This is the only study on the registry with Natural History Museum, United Kingdom as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Year to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Presently with soil-transmitted helminthiasis

Exclusion criteria

Exclusion Criteria:

  • absence of soil-transmitted helminthiasis
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
20 participants (actual)

Study arms

  • Active comparator
    1

    1 Individuals treated with Albendazole

    Drug: Albendazole

  • Active comparator
    2

    Individuals treated with Levamisole

    Drug: Levamisole

Interventions

06

What researchers measure

Primary outcomes

  1. Clearance of STH faecal eggs in patient stool

    Time frame: 18 days

07

Study locations

1 site
  • Helminth Control Laboratory Unguja
    Stone Town, Tanzania
08

References and documents

Publications

  • Stothard JR, Imison E, French MD, Sousa-Figueiredo JC, Khamis IS, Rollinson D. Soil-transmitted helminthiasis among mothers and their pre-school children on Unguja Island, Zanzibar with emphasis upon ascariasis. Parasitology. 2008 Oct;135(12):1447-55. doi: 10.1017/S0031182008004836. Epub 2008 Sep 8. PubMed 18775092 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 17, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00659997
Lead sponsor
Natural History Museum, United Kingdom
Collaborators
Ministry of Health, Tanzania, University of London
First posted
Apr 17, 2008
Start date
Jun 2006
Primary completion
Sep 2006
Completion
Sep 2007
Last update
Apr 17, 2008

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Albendazole · Levamisole

Start the discussion